Learn how biologic therapies for psoriasis work, the difference between single and dual inhibitors, and how dermatologists choose the right treatment for the individual.

Biologic drugs used to treat psoriasis were associated with lower risks for certain ocular diseases, including keratitis and ...

Objectives: (1) To develop a clinically useful model with which dermatologists can understand the potential uses of biologic therapy for psoriasis and understand the potential differences among these ...

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how ...

A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Biologic and conventional therapies were associated with comparable rates of cancer progression and recurrence among patients with psoriasis who have active cancer or who have had cancer within 5 ...

Please provide your email address to receive an email when new articles are posted on . Understanding drug survival is important for clinical prescribing and long-term disease control. Bimekizumab has ...

Learn how rotational therapy for psoriasis has evolved with the advent of safer, more effective biologic therapies.

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

Black Medicaid beneficiaries were less likely to use biologics compared with white beneficiaries in a cross-sectional study. Compared with white beneficiaries, Black beneficiaries had lower biologic ...